FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923669877> ?p ?o ?g. }

• W2923669877 abstract "Nodding syndrome is a poorly understood neurological disorder of unknown aetiology, affecting several thousand children in Africa. There has been a consistent epidemiological association with infection by the filarial parasite, Onchocerca volvulus and antibodies to leiomodin and DJ-1, cross-reacting with O.volvulus proteins, have been reported. We hypothesized that nodding syndrome is a neuro-inflammatory disorder, induced by antibodies to O.volvulus or its symbiont, Wolbachia, cross-reacting with human neuron proteins and that doxycycline, which kills Onchocerca through effects on Wolbachia, may be used as treatment. This will be a two-arm, double-blind, placebo-controlled, randomised phase II trial of doxycycline 100 mg daily for six weeks in 230 participants. Participants will be patients’ ages≥8 years with nodding syndrome. They will receive standard of care supportive treatment. All will be hospitalised for 1–2 weeks during which time baseline measurements including clinical assessments, EEG, cognitive and laboratory testing will be performed and antiepileptic drug doses rationalised. Participants will then be randomised to either oral doxycycline (Azudox®, Kampala Pharmaceutical Industries) 100 mg daily or placebo. Treatment will be initiated in hospital and continued at home. Participants will be visited at home at 2, 4 and 6 weeks for adherence monitoring. Study outcomes will be assessed at 6, 12, 18 and 24-month visits. Analysis will be by intention to treat. The primary efficacy outcome measure will be the proportion of patients testing positive and the levels or titires of antibodies to host neuron proteins (HNPs) and/or leiomodin at 24 months. Secondary outcome measures will include effect of the intervention on seizure control, inflammatory markers, cognitive function, disease severity and quality of life. This trial postulates that targeting O.volvulus through drugs which kill Wolbachia can modify the pathogenic processes in nodding syndrome and improve outcomes. Findings from this study are expected to substantially improve the understanding and treatment of nodding syndrome. Registered with clinicaltrials.gov ID: NCT02850913 on 1st August, 2016." @default.
• W2923669877 created "2019-04-01" @default.
• W2923669877 creator A5003066106 @default.
• W2923669877 creator A5014291864 @default.
• W2923669877 creator A5015602334 @default.
• W2923669877 creator A5024738923 @default.
• W2923669877 creator A5047582817 @default.
• W2923669877 creator A5049007355 @default.
• W2923669877 creator A5056925040 @default.
• W2923669877 creator A5059020333 @default.
• W2923669877 creator A5061486870 @default.
• W2923669877 creator A5061957649 @default.
• W2923669877 creator A5062939642 @default.
• W2923669877 creator A5072332085 @default.
• W2923669877 creator A5089346982 @default.
• W2923669877 date "2019-03-06" @default.
• W2923669877 modified "2023-10-16" @default.
• W2923669877 title "Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial" @default.
• W2923669877 cites W1809918102 @default.
• W2923669877 cites W1979743371 @default.
• W2923669877 cites W1981065083 @default.
• W2923669877 cites W1999186945 @default.
• W2923669877 cites W2001457674 @default.
• W2923669877 cites W2003603064 @default.
• W2923669877 cites W2005795852 @default.
• W2923669877 cites W2031615974 @default.
• W2923669877 cites W2048499352 @default.
• W2923669877 cites W2075150494 @default.
• W2923669877 cites W2075563319 @default.
• W2923669877 cites W2082270732 @default.
• W2923669877 cites W2101548438 @default.
• W2923669877 cites W2102714741 @default.
• W2923669877 cites W2107464979 @default.
• W2923669877 cites W2118105636 @default.
• W2923669877 cites W2121769876 @default.
• W2923669877 cites W2134389315 @default.
• W2923669877 cites W2138167600 @default.
• W2923669877 cites W2140527299 @default.
• W2923669877 cites W2162734057 @default.
• W2923669877 cites W2172173632 @default.
• W2923669877 cites W2300273971 @default.
• W2923669877 cites W2416445831 @default.
• W2923669877 cites W2587837928 @default.
• W2923669877 cites W2791667744 @default.
• W2923669877 cites W3171418018 @default.
• W2923669877 cites W4234421278 @default.
• W2923669877 cites W4292359492 @default.
• W2923669877 cites W4298312018 @default.
• W2923669877 doi "https://doi.org/10.1186/s12883-019-1256-z" @default.
• W2923669877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6402111" @default.
• W2923669877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30841858" @default.
• W2923669877 hasPublicationYear "2019" @default.
• W2923669877 type Work @default.
• W2923669877 sameAs 2923669877 @default.
• W2923669877 citedByCount "13" @default.
• W2923669877 countsByYear W29236698772020 @default.
• W2923669877 countsByYear W29236698772021 @default.
• W2923669877 countsByYear W29236698772022 @default.
• W2923669877 countsByYear W29236698772023 @default.
• W2923669877 crossrefType "journal-article" @default.
• W2923669877 hasAuthorship W2923669877A5003066106 @default.
• W2923669877 hasAuthorship W2923669877A5014291864 @default.
• W2923669877 hasAuthorship W2923669877A5015602334 @default.
• W2923669877 hasAuthorship W2923669877A5024738923 @default.
• W2923669877 hasAuthorship W2923669877A5047582817 @default.
• W2923669877 hasAuthorship W2923669877A5049007355 @default.
• W2923669877 hasAuthorship W2923669877A5056925040 @default.
• W2923669877 hasAuthorship W2923669877A5059020333 @default.
• W2923669877 hasAuthorship W2923669877A5061486870 @default.
• W2923669877 hasAuthorship W2923669877A5061957649 @default.
• W2923669877 hasAuthorship W2923669877A5062939642 @default.
• W2923669877 hasAuthorship W2923669877A5072332085 @default.
• W2923669877 hasAuthorship W2923669877A5089346982 @default.
• W2923669877 hasBestOaLocation W29236698771 @default.
• W2923669877 hasConcept C118552586 @default.
• W2923669877 hasConcept C126322002 @default.
• W2923669877 hasConcept C142724271 @default.
• W2923669877 hasConcept C16568411 @default.
• W2923669877 hasConcept C168563851 @default.
• W2923669877 hasConcept C187212893 @default.
• W2923669877 hasConcept C203014093 @default.
• W2923669877 hasConcept C204787440 @default.
• W2923669877 hasConcept C27081682 @default.
• W2923669877 hasConcept C2777179404 @default.
• W2923669877 hasConcept C2779027325 @default.
• W2923669877 hasConcept C2780727990 @default.
• W2923669877 hasConcept C501593827 @default.
• W2923669877 hasConcept C535046627 @default.
• W2923669877 hasConcept C71924100 @default.
• W2923669877 hasConcept C86803240 @default.
• W2923669877 hasConcept C89423630 @default.
• W2923669877 hasConceptScore W2923669877C118552586 @default.
• W2923669877 hasConceptScore W2923669877C126322002 @default.
• W2923669877 hasConceptScore W2923669877C142724271 @default.
• W2923669877 hasConceptScore W2923669877C16568411 @default.
• W2923669877 hasConceptScore W2923669877C168563851 @default.
• W2923669877 hasConceptScore W2923669877C187212893 @default.
• W2923669877 hasConceptScore W2923669877C203014093 @default.
• W2923669877 hasConceptScore W2923669877C204787440 @default.
• W2923669877 hasConceptScore W2923669877C27081682 @default.

• next